Maria R. Pitari
Catanzaro, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 15, 2024
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Journal: Molecular cancer therapeutics
Published: December 16, 2015
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.
Journal: Oncotarget
Published: May 05, 2015
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 11, 2015
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
Journal: Oncotarget
Published: February 15, 2015
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
Journal: Journal of cellular physiology
Published: February 08, 2014
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
Journal: Journal of cellular physiology
Published: November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Journal: Cell death & disease
Published: November 30, 2012
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 05, 2012
Last Updated: 09/26/2026